[ad_1]
In the event of a positive conclusion from Ema’s analysis of the AstraZeneca vaccine, the Italian Prime Minister, Mario draghi, and the President of the French Republic, Emmanuel macron, I’m ready to restart management quickly. what emerged at the end of today’s conversation between Draghi and Macron, according to a note from the presidency of the council of ministers. The analysis of the European Medicines Agency (Ema) expected Thursday March 18. Therefore, the temporary and preventive suspension of the administration of AstraZeneca doses should not last longer than four days.
The suspension will be reabsorbed in a couple of weeks.
Immediately, the preventive and temporary suspension of the administration of AstraZeneca raised concerns about its impact on the progress of the vaccination plan, which aims to immunize 80% of Italians by September 20. From the Palazzo Chigi they announced that the extraordinary commissioner for the emergency, the General Figliuolo, investigated the matter. The duration of the suspension, as announced by the extraordinary commissioner, can be estimated at a total of four days (from Monday March 15 to Thursday 18, the day on which the pronouncement of the EMA and therefore of AIFA is expected ). As for its impact, can be estimated at 200,000 fewer vaccines. If AstraZeneca resumes from March 18, says Palazzo Chigi, the slowdown could be reabsorbed in a couple of weeks, also thanks to theincrease in the amount ofPfizer vaccine estimated at 707,850 doses, we learn from the sources of the Palazzo Chigi.
AstraZeneca Vaccine Suspension: Knowledge
The vaccine suspended in Italy, France, Germany and other countries
The suspension of the use of AstraZeneca vials for the vaccination campaign was decided in Italy, France, Spain, Germany, Luxembourg and Slovenia on March 15. temporary and precautionary, after some cases of thrombosis occurred in recently vaccinated subjects (details and numbers here). Previously, other European countries had also suspended vaccines, while other states, such as Great Britain and Canada – continue to use the AstraZeneca vaccine regularly.
Ema’s opinion
Ema reiterated that the benefits of the AstraZeneca vaccine always outweigh the risks. The confirmed cases of thromboembolism after the administration of the AstraZeneca vaccine as of March 10 were 30 – the number is underestimated because more cases have been reported even over the weekend (all details here), but for now There is no indication that the vaccine caused these conditions..
AstraZeneca data
AstraZeneca also released some safety data and its vaccine. So far Europe and the UK have been vaccinated 17 million people. Among them, the company says, there were 15 deep vein thrombosis events and 22 pulmonary embolism events reported among those who have received the vaccine (data updated to March 8). The numbers, AstraZeneca notes, are lower than would be expected to occur naturally in a general population of this size. The annual incidence of thromboembolism of one case per 1,000 inhabitants explained to Messenger Service Andrea Cossarizza, Professor of General Pathology and Immunology at the University of Modena. In Italy we can expect approx. 60 thousand cases a year, 1,150 a week, 166 a day.
March 16, 2021 (change March 16, 2021 | 20:10)
© REPRODUCTION RESERVED
[ad_2]
